GENESIS Pharma

Executive Summary

GENESIS Pharma is a private biopharmaceutical company based in Athens, Greece, specializing in the commercialization of innovative medicines for serious and rare diseases across Central and Eastern Europe (CEE). Founded in 1994, it was among the first in Europe to focus on biopharmaceuticals and has since built a robust regional network. The company's portfolio targets over 30 chronic and rare conditions, primarily in neurology, oncology, hematology, and genetic disorders. By leveraging its deep understanding of local markets and regulatory environments, GENESIS Pharma acts as a strategic partner for global biopharma companies seeking to expand into the CEE region. Its business model focuses on in-licensing, distribution, and commercialization of advanced therapies, including small molecules and biologics. The company's long-standing presence and expertise position it well to capture growth in the underserved rare disease space in CEE, though it faces competition from larger multinational firms and generic manufacturers. While its private status limits visibility into financials, its track record and specialization in a niche market support a stable outlook.

Upcoming Catalysts (preview)

• TBDNew product launch in CEE for a rare genetic disorder60% success
• TBDExpansion of neurology portfolio through in-licensing50% success
• TBDStrategic partnership for oncology therapy commercialization40% success